孤立性亚段肺栓塞:抗凝与临床监测的系统评价与荟萃分析
该系统评价与荟萃分析比较了孤立性亚段肺栓塞患者接受抗凝治疗与临床监测的疗效与安全性。结果显示抗凝治疗未显著降低静脉血栓栓塞复发或全因死亡风险,但任何出血并发症发生率显著升高,现有证据不支持常规抗凝治疗。
要点
- 抗凝未显著降低iSSPE患者VTE复发风险(RR 0.61,95%CI 0.28-1.35)。
- 抗凝组任何出血并发症风险显著高于临床监测组(RR 3.10,95%CI 1.39-6.88)。
- 全因死亡率两组无显著差异(RR 0.70,95%CI 0.44-1.12)。
核心结论
- 现有证据不支持对孤立性亚段肺栓塞患者常规抗凝治疗带来净临床获益。
研究设计与样本
- 系统评价与荟萃分析,检索Medline和EMBASE截至2025年4月比较抗凝与临床监测的研究。
主要发现
- 8项观察性研究(674例)报告VTE复发,抗凝与未抗凝组无显著差异(RR 0.61,95%CI 0.28-1.35,I²=0%)。
- 9项研究(862例)报告安全性结局,抗凝组任何出血并发症发生率更高(RR 3.10,95%CI 1.39-6.88,I²=0%)。
- 限制于大出血事件的分析观察到类似关联。
- 全因死亡率两组无显著差异(RR 0.70,95%CI 0.44-1.12,I²=45%)。
关键数值与推荐
- VTE复发风险比RR 0.61(95%CI 0.28-1.35)。
- 任何出血并发症风险比RR 3.10(95%CI 1.39-6.88)。
- 全因死亡风险比RR 0.70(95%CI 0.44-1.12)。
临床怎么用
- 对iSSPE患者应审慎评估抗凝指征,权衡出血风险与血栓复发风险。
- 临床监测可能是部分iSSPE患者的合理选择,尤其出血风险较高者。
局限性
- 纳入研究均为观察性研究,可能存在选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thromb Res. 2026 May;261:109669. doi: 10.1016/j.thromres.2026.109669. Epub 2026 Apr 6. ABSTRACT INTRODUCTION: Isolated subsegmental pulmonary embolism (iSSPE) is being diagnosed with increasing frequency, but its optimal treatment remains uncertain. OBJECTIVES: This systematic review and meta-analysis aimed to investigate the efficacy and safety of anticoagulation versus clinical surveillance for the management of iSSPE. METHODS: The Medline and EMBASE databases were searched up to April 2025 for all studies that compared anticoagulation therapy against clinical surveillance in patients with iSSPE. Clinical outcomes included venous thromboembolism (VTE) recurrence, bleeding complications and all-cause mortality. Pooled risk ratios (RRs) and 95% Confidence Intervals (CI) were estimated by random-effects model. RESULTS: Eight observational studies reported data on VTE recurrence, encompassing 674 patients. The risk of VTE recurrence did not differ statistically significantly between anticoagulated and non-anticoagulated patients (RR 0.61, 95% CI 0.28-1.35, I 2 = 0%). Conversely, nine studies reported data on safety outcomes, encompassing 862 patients. The incidence of any bleeding complication was higher in anticoagulated patients compared with those managed by clinical surveillance (RR 3.10, 95% CI 1.39-6.88, I 2 = 0%). A similar association was observed when the analysis was restricted to major bleeding events. Finally, all-cause mortality did not differ statistically significantly between the two groups (RR 0.70, 95% CI 0.44-1.12, I 2 = 45%). CONCLUSIONS: Available evidence does not support a net clinical benefit from routine anticoagulation in patients with iSSPE. PMID: 41962426 | DOI: 10.1016/j.thromres.2026.109669
引用
- PubMed 高证据 · 肺栓塞:Anticoagulation therapy vs clinical surveillance in isolated subsegmental pulmonary embolism: a systematic review and meta-analysis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。